Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?

Trends Microbiol. 2015 Oct;23(10):653-665. doi: 10.1016/j.tim.2015.07.005.


Monoclonal antibodies (mAbs) are increasingly being considered as agents to fight severe viral diseases. So far, they have essentially been selected and used on the basis of their virus-neutralizing activity and/or cell-killing activity to blunt viral propagation via direct mechanisms. There is, however, accumulating evidence that they can also induce long-lasting protective antiviral immunity by recruiting the endogenous immune system of infected individuals during the period of immunotherapy. Exploiting this property may revolutionize antiviral mAb-based immunotherapies, with benefits for both patients and healthcare systems.

Keywords: Fc receptors; antiviral therapy; immune complexes; immunotherapy; monoclonal antibodies; vaccine-like effects.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Viral / immunology
  • Antibodies, Viral / therapeutic use*
  • Antiviral Agents / immunology
  • Antiviral Agents / therapeutic use*
  • Humans


  • Antibodies, Monoclonal
  • Antibodies, Viral
  • Antiviral Agents